Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:AVTE NASDAQ:GYRE NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.45+1.1%$4.10$1.22▼$5.15$621.49M0.762.04 million shs1.20 million shsAVTEAerovate Therapeutics$22.01-5.8%$18.91$89.95▼$99.05$637.96M0.9553,591 shs374,595 shsGYREGyre Therapeutics$6.26-2.8%$7.40$6.24▼$11.61$607.41M2.0390,204 shs92,694 shsORMPOramed Pharmaceuticals$4.33+0.9%$3.74$1.98▼$5.01$175.15M1.27188,773 shs285,695 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-2.65%-11.11%+3.53%+34.97%+235.88%AVTEAerovate Therapeutics0.00%-9.51%+2.21%+55.39%+217.97%GYREGyre Therapeutics-1.68%-9.17%-20.49%-21.56%-43.26%ORMPOramed Pharmaceuticals-7.54%-7.14%+10.57%+34.06%+99.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.45+1.1%$4.10$1.22▼$5.15$621.49M0.762.04 million shs1.20 million shsAVTEAerovate Therapeutics$22.01-5.8%$18.91$89.95▼$99.05$637.96M0.9553,591 shs374,595 shsGYREGyre Therapeutics$6.26-2.8%$7.40$6.24▼$11.61$607.41M2.0390,204 shs92,694 shsORMPOramed Pharmaceuticals$4.33+0.9%$3.74$1.98▼$5.01$175.15M1.27188,773 shs285,695 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-2.65%-11.11%+3.53%+34.97%+235.88%AVTEAerovate Therapeutics0.00%-9.51%+2.21%+55.39%+217.97%GYREGyre Therapeutics-1.68%-9.17%-20.49%-21.56%-43.26%ORMPOramed Pharmaceuticals-7.54%-7.14%+10.57%+34.06%+99.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.00Buy$11.29153.61% UpsideAVTEAerovate Therapeutics 0.00N/AN/AN/AGYREGyre Therapeutics 2.00Hold$17.00171.57% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ORMP, AVTE, ACRS, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/16/2026ACRSAclaris Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.004/16/2026ACRSAclaris Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.003/31/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.003/27/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/19/2026ACRSAclaris Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M79.37N/AN/A$0.85 per share5.24AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AGYREGyre Therapeutics$116.59M5.21$0.21 per share29.48$1.48 per share4.23ORMPOramed Pharmaceuticals$2M87.57$0.08 per share51.15$5.02 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/AGYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%N/AORMPOramed Pharmaceuticals$64.05M$1.492.91N/AN/AN/A-6.83%-6.25%N/ALatest ORMP, AVTE, ACRS, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026ORMPOramed PharmaceuticalsN/A$0.91N/A$0.91N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million3/27/2026Q4 2025ORMPOramed Pharmaceuticals-$0.08-$0.06+$0.02$0.24$0.50 millionN/A3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 million2/26/2026Q4 2025ACRSAclaris Therapeutics-$0.15-$0.1614-$0.0114-$0.16$2.07 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.255.72%N/A16.78%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03AVTEAerovate TherapeuticsN/A8.788.78GYREGyre TherapeuticsN/A4.644.06ORMPOramed PharmaceuticalsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AVTEAerovate TherapeuticsN/AGYREGyre Therapeutics23.99%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%AVTEAerovate Therapeutics24.90%GYREGyre Therapeutics10.00%ORMPOramed Pharmaceuticals17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableGYREGyre Therapeutics4097.03 million87.33 millionNo DataORMPOramed Pharmaceuticals1040.45 million33.25 millionOptionableORMP, AVTE, ACRS, and GYRE HeadlinesRecent News About These CompaniesOramed Pharmaceuticals Inc.May 18 at 12:32 PM | marketwatch.comOramed Pharmaceuticals Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comOramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMPMay 15, 2026 | benzinga.comOramed Pharmaceuticals IncorporatedApril 15, 2026 | edition.cnn.comOramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38March 27, 2026 | msn.comOramed: Q4 Earnings SnapshotMarch 26, 2026 | stamfordadvocate.comSLifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with OramedMarch 26, 2026 | finanznachrichten.deLifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to ProfitabilityMarch 13, 2026 | quiverquant.comQLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyMarch 13, 2026 | globenewswire.comOramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | finanznachrichten.deOramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | prnewswire.comLifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation CompanyJanuary 13, 2026 | globenewswire.comOramed stock rises after receiving $18 million payment from ScilexJanuary 7, 2026 | za.investing.comOramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsJanuary 7, 2026 | prnewswire.comOramed Pharm completes warrant sale, boosting liquidityDecember 31, 2025 | msn.comWhy Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Up 7.03%December 25, 2025 | aaii.comAOramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After SetbackDecember 24, 2025 | seekingalpha.comORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan AdoptedNovember 24, 2025 | finance.yahoo.comThere Are Some Holes In Oramed Pharmaceuticals' (NASDAQ:ORMP) Solid Earnings ReleaseNovember 21, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc.: Oramed Reports Fiscal Third Quarter 2025 Financial ResultsNovember 17, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, AVTE, ACRS, and GYRE Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.45 +0.05 (+1.14%) Closing price 04:00 PM EasternExtended Trading$4.50 +0.05 (+1.06%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Aerovate Therapeutics NASDAQ:AVTE$22.01 -1.35 (-5.76%) As of 05/18/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Gyre Therapeutics NASDAQ:GYRE$6.26 -0.18 (-2.80%) Closing price 04:00 PM EasternExtended Trading$6.26 0.00 (-0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Oramed Pharmaceuticals NASDAQ:ORMP$4.33 +0.04 (+0.93%) Closing price 04:00 PM EasternExtended Trading$4.46 +0.13 (+2.89%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
